Cobicistat
Tybost
Cytochrome P450 3A Inhibitor
NADAC/unit
N/A
No Shortage
Tier 1: 15.2%
Active Shortages
2025-10-07 Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons., Gilead Sciences, Inc.
Generic Manufacturers
GILEAD SCIENCES INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.